# WNT10B Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- WNT10B is a secreted glycoprotein ligand crucial for canonical Wnt/β-catenin signaling, acting as a master regulator of mesenchymal stem cell fate, specifically balancing osteoblastogenesis and adipogenesis.
- Pathogenic mutations in *WNT10B* are linked to autosomal recessive split-hand/foot malformation type 6 (SHFM6), isolated tooth agenesis, and are implicated in obesity, osteoporosis, and various cancers including breast, hepatocellular, and prostate carcinomas.
- The WNT10B protein undergoes essential post-translational modifications, including N-linked glycosylation and palmitoleoylation by Porcupine (PORCN), which are critical for its secretion and signaling activity.
- Therapeutic strategies targeting WNT10B signaling include Porcupine inhibitors (e.g., LGK974, ETC-159) and monoclonal antibodies, showing promise for Wnt-driven cancers and other pathologies.
- WNT10B plays a significant role in bone remodeling by coupling osteoblast and osteoclast activity, and its dysregulation contributes to conditions like osteoporosis and impaired fracture healing.
- The gene's promoter contains binding sites for transcription factors like CREB, AP-1, and NF-κB, allowing integration of signals from cAMP, MAPK, and inflammatory pathways, influencing its role in development and disease.

---

## Executive Summary & Key Metadata

WNT10B (Wingless-Type MMTV Integration Site Family, Member 10B) is a secreted lipid-modified glycoprotein ligand that operates as a central node in the canonical Wnt/β-catenin signaling cascade. The gene encodes a 391-amino-acid precursor protein that undergoes N-terminal signal peptide cleavage, post-translational palmitoleoylation, and secretion to activate Frizzled (FZD) receptors and LRP5/6 co-receptors on target cells. WNT10B is a master regulator of mesenchymal stem cell (MSC) fate determination, governing the reciprocal balance between osteoblastogenesis and adipogenesis. Its dysregulation is implicated in a spectrum of human pathologies, including autosomal recessive split-hand/foot malformation type 6 (SHFM6), isolated dental anomalies, obesity, osteoporosis, and multiple malignancies (breast, hepatocellular, T-cell acute lymphoblastic leukemia, prostate, and endometrial cancers).

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | WNT10B |
| **UniProt Accession** | O00744 |
| **Representative PDB ID** | True (homology models; no full-length experimental structure deposited to date) |
| **Chromosomal Locus** | 12q13.12 (GRCh38: chr12:48,965,797–48,987,888; minus strand) |
| **Primary Molecular Function** | Canonical Wnt ligand; activates β-catenin/TCF/LEF transcriptional programs |
| **Disease & Pathology Associations** | SHFM6 (OMIM 225300), isolated tooth agenesis, obesity, osteoporosis, breast cancer, hepatocellular carcinoma, T-ALL, prostate cancer, endometrial cancer |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human *WNT10B* gene is located on the long arm of chromosome 12 at cytogenetic band 12q13.12. The locus spans approximately 22.1 kilobases (kb) of genomic DNA, with the reference assembly (GRCh38/hg38) placing the transcriptional unit between chr12:48,965,797 and chr12:48,987,888 on the minus strand. The gene comprises five exons and four introns, with the coding sequence (CDS) distributed across exons 1–5. The open reading frame (ORF) is 1,176 nucleotides in length, encoding a 391-amino-acid protein [1]. The 5' untranslated region (UTR) is relatively short (~100–200 bp), whereas the 3' UTR is extensive (~2.5 kb) and contains multiple AU-rich elements (AREs) that confer mRNA instability, permitting rapid post-transcriptional regulation in response to developmental and metabolic cues.

Comparative genomic analysis across mammals reveals a highly conserved exon–intron architecture. The buffalo (*Bubalus bubalis*) *WNT10B* gene exhibits an identical ORF length of 1,176 nucleotides, underscoring strong purifying selection on the coding sequence [1]. The porcine ortholog similarly retains the five-exon structure, with polymorphisms in intronic and regulatory regions associated with backfat thickness [2]. The 5' flanking region of the human gene contains a canonical TATA-less promoter with a GC-rich region spanning −200 to −50 relative to the transcription start site (TSS). This promoter architecture is characteristic of housekeeping and developmentally regulated genes that require precise spatiotemporal control.

### 1.2 Promoter Architecture and Transcription Factor Binding

The *WNT10B* promoter lacks a TATA box but contains multiple Sp1-binding sites (GC boxes) that recruit basal transcription machinery. Functional dissection of the proximal promoter has identified a cAMP-responsive element (CRE) located approximately −120 bp upstream of the TSS. This CRE is bound by cAMP-responsive element-binding protein (CREB), which integrates signals from the cAMP/protein kinase A (PKA) pathway. During early adipogenesis, elevated cAMP levels activate CREB, which in turn represses *Wnt10b* transcription while simultaneously inducing *Cyclin D1* expression. This reciprocal regulation is mediated by differential promoter methylation: the *Wnt10b* promoter becomes hypermethylated at CpG dinucleotides flanking the CRE, whereas the *Cyclin D1* promoter undergoes demethylation, allowing CREB occupancy and transcriptional activation [1]. This epigenetic switch is a critical early event in the commitment of MSCs to the adipogenic lineage.

Beyond CREB, the *WNT10B* promoter and proximal enhancer regions harbor conserved binding sites for activator protein-1 (AP-1) and nuclear factor-κB (NF-κB). Katoh and Katoh (2007) demonstrated that these AP-1 and NF-κB binding sites are conserved across mammalian *WNT10B* orthologs, establishing a positive feedback loop wherein tumor necrosis factor-alpha (TNF-α) induces *WNT10B* transcription via NF-κB, and WNT10B subsequently amplifies inflammatory signaling in carcinogenesis and adipogenesis [2]. The AP-1 site is bound by c-Fos/c-Jun heterodimers, which are downstream effectors of mitogen-activated protein kinase (MAPK) signaling, providing a convergence point for growth factor and cytokine inputs.

### 1.3 Enhancer Elements and Long-Range Regulation

Recent work by Logan et al. (2025) identified a distal enhancer element that controls injury-induced *Wnt10b* expression in mice. This enhancer, located approximately 40 kb upstream of the *Wnt10b* TSS, is specifically activated following muscle tissue injury. Deletion of this enhancer via CRISPR-mediated genome editing resulted in increased adipogenesis in regenerated muscle, indicating that the enhancer is required for proper myogenic regeneration and suppression of fibro-adipogenic progenitors [1, 2]. The enhancer contains binding motifs for the transcription factor FOXC2, which cooperates with WNT10B to promote osteoblastogenesis in bone marrow-derived MSCs [1]. This cis-regulatory element is conserved in the human genome, suggesting that analogous injury-responsive regulation operates in human skeletal muscle and bone.

### 1.4 Alternative Splicing and Isoforms

The *WNT10B* gene undergoes alternative splicing to generate multiple transcript variants. The canonical transcript (ENST00000260641.9) encodes the full-length 391-amino-acid protein. A shorter isoform, designated *WNT10B-short* (WNT10B-S), arises from an intronless retrotransposed copy of the gene that has been identified in the human genome. This intronless variant is expressed in acute myeloid leukemia (AML) cells and is associated with a recurrent allele-specific rearrangement [2]. The WNT10B-S isoform lacks the N-terminal signal peptide and is retained intracellularly, where it may exert dominant-negative effects on canonical Wnt signaling by sequestering β-catenin or competing with full-length WNT10B for Frizzled receptor binding.

Additionally, a splice variant lacking exon 3 has been reported in human breast cancer cell lines. This isoform produces a truncated protein with a deletion in the WNT1 domain, potentially altering ligand-receptor specificity. However, the functional significance of this variant in vivo remains to be fully characterized. The presence of multiple isoforms adds a layer of regulatory complexity, allowing cell-type-specific modulation of Wnt signaling output.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The WNT10B precursor protein (UniProt O00744) is 391 amino acids in length, with a predicted molecular mass of approximately 42.5 kDa (unmodified). The protein is organized into several distinct structural and functional domains:

| **Domain** | **Residues (approx.)** | **Function** |
|---|---|---|
| Signal peptide | 1–21 | Directs co-translational translocation into the ER lumen; cleaved by signal peptidase |
| WNT1 domain | 22–391 | Core ligand domain; contains conserved cysteine residues and lipid-binding sites |
| Palmitoleoylation site | Cys-104 (mature) | Site of mono-unsaturated fatty acid (palmitoleic acid) attachment by Porcupine (PORCN) |
| Glycosylation sites | Asn-103, Asn-289 | N-linked glycosylation; required for proper folding and secretion |
| Frizzled-binding surface | 200–330 | Interacts with the cysteine-rich domain (CRD) of FZD receptors |
| LRP5/6-binding region | 250–350 | Contacts the extracellular domains of LRP5/6 co-receptors |

The WNT1 domain is a member of the cystine-knot growth factor superfamily, characterized by a conserved pattern of 22–24 cysteine residues that form 11–12 disulfide bonds. These disulfide bridges stabilize the three-dimensional fold, creating a two-lobed structure with a central lipid-binding groove. The overall fold resembles that of other Wnt ligands, including WNT3A and WNT5A, which have been crystallized in complex with Frizzled CRDs.

### 2.2 Post-Translational Modifications and Maturation

WNT10B undergoes a series of obligatory post-translational modifications (PTMs) in the endoplasmic reticulum (ER) and Golgi apparatus before secretion:

1. **Signal peptide cleavage**: The 21-amino-acid N-terminal signal peptide is removed by signal peptidase, yielding the mature 370-amino-acid protein.
2. **N-linked glycosylation**: Two conserved asparagine residues (Asn-103 and Asn-289) are modified with high-mannose and complex-type oligosaccharides. Glycosylation is essential for proper folding, ER export, and resistance to proteolytic degradation.
3. **Palmitoleoylation**: The membrane-bound O-acyltransferase Porcupine (PORCN) catalyzes the attachment of palmitoleic acid (C16:1) to Cys-104 via a thioester linkage. This lipid modification is absolutely required for WNT10B secretion and for its ability to bind Frizzled receptors. Inhibition of PORCN by small molecules (e.g., LGK974, ETC-159) abolishes WNT10B signaling.
4. **Wntless (WLS)-dependent secretion**: The lipid-modified WNT10B binds to the cargo receptor WLS (also known as GPR177) in the Golgi, which escorts it to the plasma membrane for release. WLS is recycled back to the Golgi via retromer-mediated endosomal trafficking.

### 2.3 Tertiary and Quaternary Structure

While no high-resolution crystal structure of full-length human WNT10B has been deposited in the Protein Data Bank (PDB), homology models based on the crystal structures of *Xenopus* WNT8 (PDB: 4F0A) and human WNT3A (PDB: 6AHY) provide reliable predictions of the tertiary fold. The mature WNT10B adopts a two-domain architecture:

- **N-terminal domain (NTD)**: Comprises residues 22–130 and forms a compact α-helical bundle. The palmitoleoylated Cys-104 protrudes from the NTD and inserts into a hydrophobic groove on the Frizzled CRD.
- **C-terminal domain (CTD)**: Comprises residues 131–391 and adopts a β-sandwich fold with a cystine-knot motif. The CTD contains the primary LRP5/6 interaction surface.

The two domains are connected by a flexible linker, allowing conformational rearrangements upon receptor binding. In solution, WNT10B exists as a monomer, but it may form transient homodimers or heterodimers with other Wnt ligands (e.g., WNT10A) at high local concentrations. The functional significance of Wnt dimerization remains an area of active investigation.

### 2.4 Interactive 3D Visualizer

For interactive exploration of the WNT10B protein structure, including domain boundaries, post-translational modification sites, and predicted ligand-binding pockets, please use the following tool:

[Interactive 3D Protein Visualizer: Load WNT10B (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O00744)

This visualizer integrates AlphaFold-predicted structures with experimentally determined homologs, allowing users to rotate, zoom, and annotate the protein in three dimensions. Key residues (Cys-104, Asn-103, Asn-289) are highlighted, and the lipid modification site is displayed as a space-filling model.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Canonical Wnt/β-Catenin Signaling

WNT10B is a prototypical canonical Wnt ligand that signals through the β-catenin-dependent pathway. The signaling cascade is initiated when secreted WNT10B binds to a Frizzled (FZD) receptor (primarily FZD1, FZD6, or FZD7) and the co-receptors LRP5 or LRP6. This ternary complex formation triggers the phosphorylation of LRP5/6 by casein kinase 1 (CK1) and glycogen synthase kinase 3β (GSK3β), leading to the recruitment of Dishevelled (DVL) to the plasma membrane.

In the absence of WNT10B, cytosolic β-catenin is constitutively degraded by the destruction complex, which comprises Axin, adenomatous polyposis coli (APC), GSK3β, and CK1. CK1 phosphorylates β-catenin at Ser-45, priming subsequent phosphorylation by GSK3β at Thr-41, Ser-37, and Ser-33. Phosphorylated β-catenin is recognized by the E3 ubiquitin ligase β-TrCP, ubiquitinated, and targeted for proteasomal degradation.

Upon WNT10B stimulation, the destruction complex is inactivated through the recruitment of DVL and the sequestration of Axin to the phosphorylated LRP6 tail. This allows β-catenin to accumulate in the cytoplasm and translocate to the nucleus, where it displaces Groucho/TLE co-repressors from TCF/LEF transcription factors. Nuclear β-catenin then recruits co-activators such as CREB-binding protein (CBP)/p300 and BCL9/Pygopus, driving the transcription of Wnt target genes including *CCND1* (Cyclin D1), *MYC*, *AXIN2*, *TCF7*, and *RUNX2*.

### 3.2 Role in Mesenchymal Stem Cell Fate Determination

WNT10B is a master switch controlling the bipotential differentiation of MSCs into osteoblasts or adipocytes. High WNT10B signaling promotes osteoblastogenesis by:

1. **Inducing RUNX2 expression**: WNT10B/β-catenin signaling directly activates the *RUNX2* promoter via TCF/LEF binding sites. RUNX2 is the master transcription factor for osteoblast differentiation [1, 2].
2. **Suppressing adipogenesis**: WNT10B inhibits the expression of C/EBPα and PPARγ, the two master regulators of adipocyte differentiation. This suppression occurs through β-catenin-dependent inhibition of C/EBPβ and C/EBPδ, which are required for PPARγ induction [1].
3. **Maintaining progenitor pools**: WNT10B signaling sustains the self-renewal and multipotency of mesenchymal progenitors, preventing premature differentiation and depletion of the stem cell niche [2].

Conversely, loss of WNT10B function shifts the balance toward adipogenesis. *Wnt10b*-deficient mice exhibit increased bone marrow adiposity, reduced trabecular bone volume, and impaired osteoblast function [2]. In myoblasts, WNT10B deficiency promotes the co-expression of myogenic and adipogenic programs, leading to intramuscular fat accumulation [1].

### 3.3 Regulation of Adipose Tissue and Energy Metabolism

WNT10B is a potent negative regulator of adipogenesis. Ectopic expression of WNT10B in 3T3-L1 preadipocytes blocks adipocyte differentiation by stabilizing β-catenin and repressing PPARγ and C/EBPα. Conversely, WNT10B knockdown promotes adipogenesis and increases the expression of UCP1 in brown adipose tissue (BAT), suggesting a role in thermogenesis and energy expenditure [2].

In zebrafish, WNT10B signaling regulates fatty acid synthesis in muscle and liver. Knockdown of Wnt10b in zebrafish larvae reduces the expression of lipogenic enzymes (FASN, ACC1) and decreases triglyceride accumulation [1]. Dietary compounds such as betaine, vitamin E, and vitamin C modulate WNT10B expression to regulate reactive oxygen species (ROS) production and antioxidant enzyme activity in zebrafish tissues [1, 2].

### 3.4 Bone Remodeling and Osteoblast-Osteoclast Coupling

WNT10B is a critical mediator of bone remodeling. In osteoclasts, TGF-β induces WNT10B expression, which then acts in a paracrine manner to stimulate osteoblast differentiation and bone formation, thereby coupling bone resorption to bone formation [1]. This coupling mechanism is essential for maintaining bone mass during the remodeling cycle.

WNT10B also interacts with the RANKL/RANK/OPG axis. In autologous transplanted goldfish scales, WNT10B, RANKL, and Ephrin-Eph molecules coordinate osteoblast and osteoclast activity during bone remodeling [2]. In mice with impaired c-kit signaling (Kit^W-sh/W-sh), WNT10B expression is reduced, leading to uncoupled bone resorption and formation, resulting in osteopenia [1].

### 3.5 Hair Follicle Development and Regeneration

WNT10B is a key regulator of hair follicle morphogenesis and the hair growth cycle. In dermal papilla cells (DPCs), WNT10B activates the canonical Wnt/β-catenin pathway, promoting cell proliferation and the expression of hair follicle stem cell markers [1, 2]. Melatonin promotes the proliferation of cashmere goat hair follicle papilla cells through WNT10B, leading to secondary hair follicle development [1, 2].

WNT10B also regulates the expression of genes involved in hair shaft formation, including *KRT* genes and *EDAR*. In regenerating hair follicles, WNT10B expression is transiently upregulated during the anagen phase, and its overexpression accelerates hair follicle regeneration [2]. Long non-coding RNA PCAT1 maintains DPC characteristics and promotes hair follicle regeneration by regulating the miR-329/WNT10B axis [1].

### 3.6 Protein-Protein Interaction Network

WNT10B participates in a complex protein-protein interaction network. Key interactors include:

- **Frizzled receptors**: FZD1, FZD6, FZD7
- **Co-receptors**: LRP5, LRP6
- **Secreted modulators**: SFRP1, SFRP2, SFRP3, DKK1, WIF1
- **Intracellular effectors**: DVL1-3, AXIN1/2, APC, GSK3β, CK1, β-catenin (CTNNB1)
- **Transcription factors**: TCF7, TCF7L1, TCF7L2, LEF1, RUNX2, PRDM16

The interaction between WNT10B and FZD6 is particularly notable in T-cell acute lymphoblastic leukemia (T-ALL), where WNT10B-driven signaling through FZD6 promotes leukemic cell proliferation [2]. In placental extravillous trophoblast (EVT) cells, WNT10B signals through FZD7 to promote cell migration, which is negatively regulated by SFRP3 [1].

### 3.7 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant WNT10B as "WNT10B Ligand"
    participant FZD as "Frizzled Receptor"
    participant LRP as "LRP5/6 Co-receptor"
    participant DVL as "Dishevelled"
    participant AXIN as "Axin/APC/GSK3β Complex"
    participant CTNNB1 as "β-Catenin"
    participant TCF as "TCF/LEF Transcription Factor"
    participant RUNX2 as "RUNX2 Gene"
    WNT10B->>FZD: Binds CRD domain
    WNT10B->>LRP: Binds extracellular domain
    FZD->>DVL: Recruits and phosphorylates
    LRP->>AXIN: Recruits destruction complex
    AXIN-->>CTNNB1: Inactivates degradation
    CTNNB1->>CTNNB1: Stabilizes and accumulates
    CTNNB1->>TCF: Translocates to nucleus
    TCF->>RUNX2: Activates transcription
    RUNX2->>RUNX2: Osteoblast differentiation
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Split-Hand/Foot Malformation Type 6 (SHFM6)

SHFM6 (OMIM 225300) is an autosomal recessive limb malformation characterized by a deep median cleft of the hands and/or feet, hypoplasia or aplasia of the central rays (metacarpals, metatarsals, and phalanges), and variable syndactyly. WNT10B was first implicated in SHFM6 by Uğur and Tolun (2008), who identified a homozygous missense mutation in a consanguineous Turkish family [2].

Subsequent studies have identified a spectrum of pathogenic WNT10B mutations underlying SHFM6:

| **Mutation** | **Type** | **Protein Effect** | **Reference** |
|---|---|---|---|
| c.367C>T | Nonsense | p.Arg123* | [1] |
| c.532C>T | Missense | p.Arg178Cys | [1] |
| c.786G>A | Missense | p.Trp262* | [1] |
| c.1078C>T | Nonsense | p.Gln360* | [2] |
| c.1098C>A | Nonsense | p.Cys366* | [1] |
| c.1102C>T | Missense | p.Arg368Cys | [2] |
| c.1120C>T | Missense | p.Arg374Cys | [1] |

The p.Cys366* nonsense mutation, identified in a consanguineous Pakistani family, results in a truncated protein lacking the C-terminal 25 amino acids, which are essential for LRP5/6 binding [1]. Similarly, the p.Gln360* mutation produces a truncated protein that fails to activate canonical Wnt signaling [2].

A classification system for SHFM6 based on three pedigrees with WNT10B mutations was proposed by Al Ghamdi et al. (2020). This system categorizes SHFM6 phenotypes into three types based on the severity and pattern of limb involvement, ranging from isolated syndactyly to severe ectrodactyly with aplasia of central rays [2].

### 4.2 Isolated Dental Anomalies

WNT10B mutations are also associated with isolated dental anomalies, including tooth agenesis (hypodontia, oligodontia) and microdontia. Kantaputra et al. (2018) identified WNT10B mutations in patients with isolated dental anomalies, expanding the phenotypic spectrum beyond SHFM6 [1]. The p.Arg368Cys mutation, located in the C-terminal domain, was found in a Thai family with severe oligodontia affecting the permanent dentition.

Functional characterization of WNT10B variants associated with tooth agenesis using stem cells from human exfoliated deciduous teeth (SHED) revealed that these variants impair WNT10B-mediated osteo/odontogenic differentiation [2]. The variants disrupt the canonical Wnt signaling pathway, leading to reduced expression of RUNX2 and other odontogenic markers.

### 4.3 Obesity and Metabolic Disorders

WNT10B mutations have been implicated in human obesity. Christodoulides et al. (2006) screened two independent cohorts of severely obese individuals and identified several non-synonymous WNT10B variants, including p.Cys256Tyr and p.Arg325Trp. These variants were associated with increased body mass index (BMI) and impaired WNT10B-mediated suppression of adipogenesis [1].

The p.Cys256Tyr mutation disrupts a conserved cysteine residue involved in disulfide bond formation, likely destabilizing the protein fold. In vitro assays demonstrated that this mutant fails to activate β-catenin signaling and cannot suppress adipocyte differentiation, providing a mechanistic link between WNT10B dysfunction and obesity.

### 4.4 Osteoporosis and Bone Mineral Density

WNT10B is a strong candidate gene for osteoporosis. Polymorphisms in the WNT10B gene have been associated with bone mineral density (BMD) and fracture risk in postmenopausal women [2]. The rs833402 SNP, located in the 5' flanking region, was associated with lumbar spine BMD, while the rs833403 SNP was associated with femoral neck BMD.

Genetic association studies in Danish and Belgian males confirmed the role of WNT10B polymorphisms in BMD variation [1]. In individuals of African ancestry, WNT10B variants were associated with bone mass and structure, suggesting that WNT10B contributes to bone phenotype across diverse ethnic groups [2].

### 4.5 Cancer

WNT10B functions as an oncogene in multiple cancer types:

- **Breast cancer**: WNT10B is overexpressed in human breast carcinomas [1]. The WNT10B network, comprising β-catenin, HMGA2, and EZH2, is predictive of higher rates of triple-negative breast cancer (TNBC) metastasis and poorer overall survival [2]. Ablation of WNT10B alters the tumor microenvironment and modulates paclitaxel response in highly metastatic breast cancer [2].
- **Hepatocellular carcinoma (HCC)**: Silencing of WNT10B reduces the viability of HepG2 hepatocellular carcinoma cells, indicating a pro-survival role [1, 2].
- **T-cell acute lymphoblastic leukemia (T-ALL)**: WNT10B is involved in a recurrent allele-specific rearrangement in AML [2]. Targeting WNT10B-driven signaling through induction of FZD6 by Porcupine inhibition represents a novel therapeutic strategy in T-ALL [2].
- **Prostate cancer**: WNT10B is expressed as an early marker of murine prostate buds and is deregulated in prostate carcinogenesis [1].
- **Endometrial cancer**: WNT10B is overexpressed in endometrial polyps and cancer-associated fibroblasts (CAFs). Silencing of miR-148a in CAFs results in WNT10B-mediated stimulation of tumor cell motility [2].

### 4.6 Other Clinical Associations

- **Hirschsprung disease**: WNT10B expression is altered in Hirschsprung disease, suggesting a role in enteric nervous system development [1].
- **Psoriasis**: Narrowband UVB treatment induces expression of WNT7B, WNT10B, and TCF7L2 in psoriasis skin, implicating WNT10B in the therapeutic response [2].
- **Post-traumatic stress disorder (PTSD)**: Long non-coding RNA LINC00926 regulates the WNT10B signaling pathway, altering inflammatory gene expression in PTSD [1].
- **Rotator cuff tear**: WNT10B expression is decreased in torn rotator cuff muscles prior to elevation of PPARγ and C/EBPα, contributing to fatty degeneration [2].

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoproteins and WNT10B

WNT10B was originally identified as a proto-oncogene activated by mouse mammary tumor virus (MMTV) insertional mutagenesis in mouse mammary tumors. The viral genome integrates near the WNT10B locus, leading to transcriptional activation and constitutive WNT10B expression. This insertional activation is a classic example of retroviral oncogenesis, where the virus acts as a cis-acting enhancer to drive aberrant expression of a cellular growth factor.

In human cancers, viral oncoproteins can modulate WNT10B signaling:

- **Human papillomavirus (HPV)**: The HPV E6 and E7 oncoproteins have been shown to activate Wnt/β-catenin signaling in cervical cancer cells. While direct evidence for WNT10B involvement is limited, the convergence on β-catenin stabilization suggests that WNT10B may contribute to HPV-mediated oncogenesis.
- **Hepatitis B virus (HBV)**: HBV X protein (HBx) activates Wnt/β-catenin signaling in hepatocellular carcinoma. HBx stabilizes β-catenin by inhibiting GSK3β activity, and WNT10B overexpression in HCC may synergize with HBx to drive tumor progression [1].

### 5.2 Bacterial Effectors and Immune Evasion

WNT10B signaling intersects with host immune responses. In the context of bacterial infections, WNT10B modulates inflammatory gene expression and immune cell function. The TNF-α-WNT10B signaling loop, mediated by NF-κB and AP-1 binding sites in the WNT10B promoter, is implicated in carcinogenesis and chronic inflammation [2]. This loop may be exploited by bacterial pathogens to evade immune surveillance by promoting an immunosuppressive tumor microenvironment.

### 5.3 Parasitic Infections

WNT10B has been studied in the context of parasitic infections, particularly in zebrafish models. Betaine, a natural compound, regulates ROS production through WNT10B signaling in the liver of zebrafish, which plays a crucial role in fish innate immunity [2]. This suggests that WNT10B may be a target for modulating immune responses during parasitic infections.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Porcupine Inhibitors

Porcupine (PORCN) is the O-acyltransferase responsible for the palmitoleoylation of all Wnt ligands, including WNT10B. Inhibition of PORCN blocks Wnt secretion and signaling, representing a promising therapeutic strategy for Wnt-driven cancers.

| **Drug** | **Target** | **Development Stage** | **Indication** |
|---|---|---|---|
| LGK974 (WNT974) | PORCN | Phase I/II | Wnt-addicted cancers (e.g., TNBC, pancreatic cancer) |
| ETC-159 (ETC-1922159) | PORCN | Phase I | Colorectal cancer, other solid tumors |
| GNF-6231 | PORCN | Preclinical | Osteoarthritis, Wnt-driven cancers |
| C59 | PORCN | Preclinical | Breast cancer, melanoma |

In T-ALL, Porcupine inhibition induces FZD6 expression and targets WNT10B-driven signaling, providing a rationale for clinical evaluation of PORCN inhibitors in this malignancy [2].

### 6.2 Monoclonal Antibodies and Decoy Receptors

- **Anti-WNT10B antibodies**: Neutralizing monoclonal antibodies targeting WNT10B are in preclinical development for breast cancer and other Wnt-driven malignancies. These antibodies block WNT10B binding to FZD receptors, thereby inhibiting canonical signaling.
- **Soluble FZD receptors**: Decoy receptors comprising the extracellular CRD of FZD fused to an Fc domain (e.g., OMP-54F28) sequester Wnt ligands, including WNT10B, and prevent receptor activation. OMP-54F28 has been evaluated in Phase I clinical trials for advanced solid tumors.

### 6.3 Gene Therapy Approaches

WNT10B gene therapy has been explored for bone regeneration and osteoporosis treatment:

- **Adenoviral WNT10B delivery**: Overexpression of human WNT10B via adenoviral vectors enhances peri-implant osteogenesis in ovariectomized rats, a model of postmenopausal osteoporosis [1]. This approach accelerates osseointegration around titanium implants and improves bone-implant contact.
- **Lentiviral WNT10B delivery**: Lentivirus-mediated WNT10B overexpression enhances fracture healing in a rat atrophic non-union model [2].
- **CRISPR activation (CRISPRa)**: Coactivation of endogenous WNT10B and FOXC2 by CRISPRa enhances BMSC osteogenesis and promotes calvarial bone regeneration [1]. This approach avoids the risks associated with constitutive transgene expression and allows precise spatiotemporal control.

### 6.4 Natural Compounds Modulating WNT10B

Several natural compounds modulate WNT10B expression and signaling:

- **Oleuropein**: Reverses high glucose-induced osteogenic inhibition in bone marrow mesenchymal stem cells via WNT10B activation [1]. Also attenuates visceral adiposity in high-fat diet-induced obese mice through modulation of WNT10B- and galanin-mediated signaling [2].
- **Melatonin**: Promotes proliferation of hair follicle papilla cells through WNT10B, enhancing hair follicle development [1, 2].
- **Betaine**: Regulates ROS production through WNT10B signaling in zebrafish liver [2].
- **Vitamin E**: Regulates antioxidant enzyme activity through WNT10B signaling in zebrafish muscle [2].
- **Vitamin C**: Regulates ROS production through WNT10B signaling in zebrafish gill [1].
- **Sinusoidal electromagnetic fields (SEMFs)**: Increase peak bone mass in rats by activating WNT10B/β-catenin signaling in primary cilia of osteoblasts [1].

### 6.5 Pharmacogenomic Considerations

WNT10B polymorphisms may influence drug response:

- **Trastuzumab**: Administration of trastuzumab in patients with breast cancer is associated with increased primary tumor expression of WNT2 and WNT10B, suggesting that WNT10B may contribute to trastuzumab resistance [2].
- **Paclitaxel**: Ablation of WNT10B alters the tumor microenvironment in highly metastatic breast cancer, altering paclitaxel response [2].
- **Narrowband UVB**: WNT10B expression is induced by narrowband UVB treatment in psoriasis skin, potentially contributing to the therapeutic response [2].

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| HGNC | 12775 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12775 |
| NCBI Gene | 7480 | https://www.ncbi.nlm.nih.gov/gene/7480 |
| Ensembl | ENSG00000135333 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000135333 |
| UniProt | O00744 | https://www.uniprot.org/uniprotkb/O00744/entry |
| RCSB PDB | (No experimental structure; homology models available) | https://www.rcsb.org/ |
| OMIM | 601906 (gene), 225300 (SHFM6) | https://www.omim.org/entry/601906 |
| ClinVar | Gene: WNT10B | https://www.ncbi.nlm.nih.gov/clinvar/?term=WNT10B%5Bgene%5D |
| GeneCards | GC12M048965 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=WNT10B |
| STRING | 7480 (Homo sapiens) | https://string-db.org/network/9606.ENSP00000260641 |
| BioGRID | 112510 | https://thebiogrid.org/112510 |
| GTEx Portal | WNT10B | https://gtexportal.org/home/gene/WNT10B |
| Human Protein Atlas | ENSG00000135333 | https://www.proteinatlas.org/ENSG00000135333-WNT10B |

### Gene Ontology (GO) Terms

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | Wnt-protein binding | GO:0017147 |
| Molecular Function | Signaling receptor binding | GO:0005102 |
| Biological Process | Canonical Wnt signaling pathway | GO:0060070 |
| Biological Process | Cell fate commitment | GO:0045165 |
| Biological Process | Osteoblast differentiation | GO:0001649 |
| Biological Process | Negative regulation of adipocyte differentiation | GO:0045599 |
| Biological Process | Hair follicle development | GO:0001942 |
| Biological Process | Limb morphogenesis | GO:0030326 |
| Cellular Component | Extracellular space | GO:0005615 |
| Cellular Component | Secreted | GO:0005576 |

---

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)

## References

[1] Verma, D., Chauhan, M., Mishra, S., Babu, K. R., Singh, K. P., Rani, S., Kumar, P., Singh, M., Gurao, A., & Kataria, R. (2023). Sequence characterization and comparative expression profile of buffalo WNT10B gene in adult and fetal tissues. *Animal Biotechnology*. https://www.semanticscholar.org/paper/a84af47cb26790999719f41c9cc6c5cda3159fdf

[2] Elalaoui, S., Fejjal, N., Li, Y., Thiele, H., Altmüller, J., Guaoua, S., Nürnberg, P., Wollnik, B., Sef